JP2020511529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511529A5 JP2020511529A5 JP2019568594A JP2019568594A JP2020511529A5 JP 2020511529 A5 JP2020511529 A5 JP 2020511529A5 JP 2019568594 A JP2019568594 A JP 2019568594A JP 2019568594 A JP2019568594 A JP 2019568594A JP 2020511529 A5 JP2020511529 A5 JP 2020511529A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- stimulus
- vector
- cell
- payload
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 76
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 27
- 102000040430 polynucleotide Human genes 0.000 claims description 27
- 108091033319 polynucleotide Proteins 0.000 claims description 27
- 239000002157 polynucleotide Substances 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 239000002955 immunomodulating agent Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 15
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 14
- 230000006870 function Effects 0.000 claims description 14
- 210000002865 immune cell Anatomy 0.000 claims description 14
- 239000012636 effector Substances 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 8
- 229960000485 methotrexate Drugs 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 108091027981 Response element Proteins 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 230000001687 destabilization Effects 0.000 claims description 4
- 230000004068 intracellular signaling Effects 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims description 4
- 230000006641 stabilisation Effects 0.000 claims description 4
- 238000011105 stabilization Methods 0.000 claims description 4
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 4
- 102220526135 Dihydrofolate reductase_N65F_mutation Human genes 0.000 claims description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 239000013607 AAV vector Substances 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims description 2
- 102220526133 Dihydrofolate reductase_Q36K_mutation Human genes 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 230000000368 destabilizing effect Effects 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000004044 response Effects 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000007026 protein scission Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 101000908713 Homo sapiens Dihydrofolate reductase Proteins 0.000 description 61
- 239000012634 fragment Substances 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 102220242566 rs754509338 Human genes 0.000 description 5
- 102220503901 Meiotic recombination protein REC8 homolog_D142G_mutation Human genes 0.000 description 4
- 102200080790 rs1057520333 Human genes 0.000 description 4
- -1 CD8α Proteins 0.000 description 3
- 102220640185 Mitochondrial 2-oxoglutarate/malate carrier protein_K99R_mutation Human genes 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 102220140761 rs761526437 Human genes 0.000 description 3
- 102220159135 rs764865890 Human genes 0.000 description 3
- 102220227609 rs913563840 Human genes 0.000 description 3
- 102220546996 Actin, gamma-enteric smooth muscle_I72K_mutation Human genes 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 102200013899 rs10258719 Human genes 0.000 description 2
- 102200009188 rs148176750 Human genes 0.000 description 2
- 102220257199 rs1553408408 Human genes 0.000 description 2
- 102220283791 rs1555932650 Human genes 0.000 description 2
- 102220269760 rs182535774 Human genes 0.000 description 2
- 102200065445 rs193929333 Human genes 0.000 description 2
- 102220005448 rs28928876 Human genes 0.000 description 2
- 102200127053 rs34177811 Human genes 0.000 description 2
- 102220061202 rs786203440 Human genes 0.000 description 2
- 102220072342 rs794728994 Human genes 0.000 description 2
- 102220087418 rs864622444 Human genes 0.000 description 2
- 102220087233 rs864622667 Human genes 0.000 description 2
- 102220096012 rs876658305 Human genes 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102220495814 Actin-like protein 10_K156R_mutation Human genes 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 102220578645 Chorion-specific transcription factor GCMb_N65A_mutation Human genes 0.000 description 1
- 102220578647 Chorion-specific transcription factor GCMb_N65D_mutation Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102220553748 Cyclic GMP-AMP synthase_K47R_mutation Human genes 0.000 description 1
- 102220626226 DNA-directed primase/polymerase protein_M112T_mutation Human genes 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 102220526130 Dihydrofolate reductase_N65S_mutation Human genes 0.000 description 1
- 102220526132 Dihydrofolate reductase_Q36S_mutation Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102220545605 Endonuclease III-like protein 1_I176T_mutation Human genes 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102220511074 Hydroxycarboxylic acid receptor 3_E31D_mutation Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102220517095 Jerky protein homolog-like_I72V_mutation Human genes 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102220525890 NADH-ubiquinone oxidoreductase chain 4L_I61T_mutation Human genes 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 108010017405 NRH - quinone oxidoreductase2 Proteins 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 102220491272 Peripheral myelin protein 22_L80P_mutation Human genes 0.000 description 1
- 102220516830 Peroxisomal membrane protein PEX14_K56E_mutation Human genes 0.000 description 1
- 102220640878 Pregnancy-specific beta-1-glycoprotein 3_L23S_mutation Human genes 0.000 description 1
- 102220533819 Protein BEX2_K19E_mutation Human genes 0.000 description 1
- 102220467332 Protein BEX4_L94A_mutation Human genes 0.000 description 1
- 102220621011 Protein SGT1 homolog_Y157R_mutation Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100022353 Ribosyldihydronicotinamide dehydrogenase [quinone] Human genes 0.000 description 1
- 102220561604 SH2B adapter protein 2_W114R_mutation Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 102220419550 c.160G>A Human genes 0.000 description 1
- 102220349478 c.40T>A Human genes 0.000 description 1
- 102220383755 c.422A>G Human genes 0.000 description 1
- 102220363676 c.444T>G Human genes 0.000 description 1
- 102220398030 c.50T>A Human genes 0.000 description 1
- 102200061322 c.551A>G Human genes 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 102200081454 rs1048108 Human genes 0.000 description 1
- 102220010999 rs104894360 Human genes 0.000 description 1
- 102220195383 rs1057517839 Human genes 0.000 description 1
- 102200052983 rs1137100 Human genes 0.000 description 1
- 102200111538 rs117209107 Human genes 0.000 description 1
- 102200058933 rs121909535 Human genes 0.000 description 1
- 102220280971 rs1253463092 Human genes 0.000 description 1
- 102220289727 rs1253463092 Human genes 0.000 description 1
- 102200090745 rs137852499 Human genes 0.000 description 1
- 102200026990 rs137852764 Human genes 0.000 description 1
- 102220078654 rs147697562 Human genes 0.000 description 1
- 102220288810 rs1554539977 Human genes 0.000 description 1
- 102200004203 rs199472685 Human genes 0.000 description 1
- 102220271089 rs200048921 Human genes 0.000 description 1
- 102220150245 rs200516165 Human genes 0.000 description 1
- 102220294276 rs202032682 Human genes 0.000 description 1
- 102200068687 rs281865206 Human genes 0.000 description 1
- 102200068694 rs281865207 Human genes 0.000 description 1
- 102200065572 rs28364364 Human genes 0.000 description 1
- 102200037023 rs387907270 Human genes 0.000 description 1
- 102220021057 rs397508897 Human genes 0.000 description 1
- 102200164348 rs41295282 Human genes 0.000 description 1
- 102220326936 rs45517095 Human genes 0.000 description 1
- 102220044643 rs587781450 Human genes 0.000 description 1
- 102200001847 rs587782995 Human genes 0.000 description 1
- 102200027869 rs62517167 Human genes 0.000 description 1
- 102200103842 rs6436669 Human genes 0.000 description 1
- 102220032039 rs67418243 Human genes 0.000 description 1
- 102200101879 rs72556290 Human genes 0.000 description 1
- 102200101881 rs72556293 Human genes 0.000 description 1
- 102220057450 rs730881811 Human genes 0.000 description 1
- 102220286181 rs730881811 Human genes 0.000 description 1
- 102200094314 rs74315399 Human genes 0.000 description 1
- 102220232854 rs766277488 Human genes 0.000 description 1
- 102220082831 rs780379280 Human genes 0.000 description 1
- 102220063397 rs786204865 Human genes 0.000 description 1
- 102220323326 rs796360127 Human genes 0.000 description 1
- 102220022272 rs80357266 Human genes 0.000 description 1
- 102200067619 rs80357382 Human genes 0.000 description 1
- 102220119381 rs886042300 Human genes 0.000 description 1
- 102220235606 rs925977838 Human genes 0.000 description 1
- 102220279469 rs992385562 Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023139792A JP2023164900A (ja) | 2017-03-03 | 2023-08-30 | 免疫療法のためのｃｄ１９組成物及び方法 |
| JP2025165390A JP2025185029A (ja) | 2017-03-03 | 2025-10-01 | 免疫療法のためのｃｄ１９組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762466601P | 2017-03-03 | 2017-03-03 | |
| US62/466,601 | 2017-03-03 | ||
| US201762484052P | 2017-04-11 | 2017-04-11 | |
| US62/484,052 | 2017-04-11 | ||
| PCT/US2018/020741 WO2018161017A1 (en) | 2017-03-03 | 2018-03-02 | Cd19 compositions and methods for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023139792A Division JP2023164900A (ja) | 2017-03-03 | 2023-08-30 | 免疫療法のためのｃｄ１９組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511529A JP2020511529A (ja) | 2020-04-16 |
| JP2020511529A5 true JP2020511529A5 (enExample) | 2021-04-15 |
| JP7341900B2 JP7341900B2 (ja) | 2023-09-11 |
Family
ID=63371272
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568594A Active JP7341900B2 (ja) | 2017-03-03 | 2018-03-02 | 免疫療法のためのｃｄ１９組成物及び方法 |
| JP2023139792A Pending JP2023164900A (ja) | 2017-03-03 | 2023-08-30 | 免疫療法のためのｃｄ１９組成物及び方法 |
| JP2025165390A Pending JP2025185029A (ja) | 2017-03-03 | 2025-10-01 | 免疫療法のためのｃｄ１９組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023139792A Pending JP2023164900A (ja) | 2017-03-03 | 2023-08-30 | 免疫療法のためのｃｄ１９組成物及び方法 |
| JP2025165390A Pending JP2025185029A (ja) | 2017-03-03 | 2025-10-01 | 免疫療法のためのｃｄ１９組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3589646A4 (enExample) |
| JP (3) | JP7341900B2 (enExample) |
| KR (1) | KR102746901B1 (enExample) |
| CN (1) | CN110831961B (enExample) |
| AU (2) | AU2018227583B2 (enExample) |
| SG (2) | SG10202001869VA (enExample) |
| WO (1) | WO2018161017A1 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11241485B2 (en) | 2017-06-12 | 2022-02-08 | Obsidian Therapeutics, Inc. | PDE5 compositions and methods for immunotherapy |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
| WO2019118918A1 (en) * | 2017-12-15 | 2019-06-20 | Aleta Biotherapeutics Inc. | Cd19 variants |
| KR102907902B1 (ko) * | 2018-08-01 | 2026-01-02 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 |
| US12421524B2 (en) | 2018-09-24 | 2025-09-23 | Merck Sharp & Dohme Llc | Expression vectors for eukaryotic expression systems |
| CN113853437A (zh) * | 2018-11-07 | 2021-12-28 | 阿库斯股份有限公司 | 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| WO2020123716A1 (en) * | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| KR20250116790A (ko) | 2018-12-12 | 2025-08-01 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| WO2020156335A1 (zh) * | 2019-01-29 | 2020-08-06 | 上海交通大学 | 一种嵌合抗原受体及其应用 |
| AU2020218446B2 (en) * | 2019-02-04 | 2023-05-25 | National University Corporation Ehime University | "CAR LIBRARY AND scFv MANUFACTURING METHOD |
| KR20210132668A (ko) * | 2019-02-21 | 2021-11-04 | 아르벨 리미티드 | 인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포 |
| CN113811549A (zh) | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
| US12590135B2 (en) | 2019-03-01 | 2026-03-31 | Universität Für Bodenkultur Wien | Stabilized extracellular domain of CD19 |
| KR20210137085A (ko) * | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| BR112021017744A2 (pt) * | 2019-03-08 | 2021-11-16 | Obsidian Therapeutics Inc | Composições e métodos de cd40l para regulação ajustável |
| BR112021017770A2 (pt) * | 2019-03-08 | 2021-11-16 | Obsidian Therapeutics Inc | Composições e métodos de cd40l para regulação ajustável |
| CN113710697A (zh) * | 2019-03-15 | 2021-11-26 | 美国政府(由卫生和人类服务部的部长所代表) | 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途 |
| BR112021021178A2 (pt) * | 2019-04-26 | 2022-03-15 | Allogene Therapeutics Inc | Receptores de antígeno quimérico resistentes ao rituximabe e usos destes |
| CN110079504A (zh) * | 2019-05-06 | 2019-08-02 | 山东大学第二医院 | 一种含有不稳定结构域的car-t细胞及其制备方法和调节car-t细胞功能方法 |
| CN110075275B (zh) * | 2019-05-15 | 2023-03-24 | 苏州大学 | IL-36β的应用 |
| US20220162644A1 (en) * | 2019-05-29 | 2022-05-26 | Orbis Health Solutions, Llc | Delivery vectors and particles for expressing chimeric receptors and methods of using the same |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CA3140668A1 (en) * | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| AU2020291946B2 (en) * | 2019-06-14 | 2026-08-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| CN110818803B (zh) * | 2019-07-24 | 2023-01-03 | 浙江启新生物技术有限公司 | 分泌表达il15ra-il15融合蛋白、ccl21趋化因子的嵌合抗原受体-t细胞及应用 |
| AU2020331963A1 (en) * | 2019-08-19 | 2022-03-03 | Elpis Biopharmaceuticals | Anti-CD19 antibodies and uses thereof |
| US20210128617A1 (en) * | 2019-08-27 | 2021-05-06 | The Trustees Of The University Of Pennsylvania | SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| WO2021046451A1 (en) * | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 一种嵌合抗原受体及其用途 |
| AU2020361683A1 (en) * | 2019-10-11 | 2022-05-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia |
| EP4065696A4 (en) * | 2019-11-27 | 2024-02-07 | Board of Regents, The University of Texas System | Large-scale combined car transduction and crispr gene editing of t cells |
| WO2021108543A1 (en) * | 2019-11-27 | 2021-06-03 | The Trustees Of The University Of Pennsylvania | Anti-cd3 scfv and cytokine producing artificial antigen presenting cells |
| AU2021205416B2 (en) * | 2020-01-08 | 2026-08-06 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| JP7439280B2 (ja) * | 2020-02-13 | 2024-02-27 | イミュノファーム テクノロジー カンパニー リミテッド | キメラ抗原受容体の最適化 |
| CN115427451B (zh) * | 2020-02-14 | 2026-02-17 | 北京永泰瑞科生物科技有限公司 | 过表达从外部导入的细胞信号调节因子的免疫细胞及其用途 |
| US11896619B2 (en) * | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
| IL296242A (en) * | 2020-03-10 | 2022-11-01 | Massachusetts Inst Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
| CN113214396B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| CN114057874B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| IL300903A (en) * | 2020-09-02 | 2023-04-01 | Nkarta Inc | Expansion and enhanced cytotoxicity of natural killer cells and their uses |
| EP4208176A4 (en) * | 2020-09-04 | 2025-06-25 | Gavish-Galilee Bio Applications Ltd. | Constructs of the bicistronic inhibiting chimeric antigen receptor (ICAR)/activating chimeric antigen receptor (ACAR) for use in cancer therapies |
| US20230220025A1 (en) * | 2020-09-04 | 2023-07-13 | Heartseed Inc. | Quality Improving Agent for IPS Cells, Method of Producing IPS Cells, IPS Cells, and Composition for Producing IPS Cells |
| WO2022109443A1 (en) * | 2020-11-23 | 2022-05-27 | The Regents Of The University Of Michigan | Single-chain antibody against flavivirus ns1 protein |
| CN112830974B (zh) * | 2021-01-08 | 2022-07-26 | 深圳市珈钰生物科技有限公司 | 一种嵌合抗原受体、载体、人树突状细胞、细胞系、实体肿瘤治疗药物及制备方法和应用 |
| US20240115607A1 (en) * | 2021-01-26 | 2024-04-11 | Cytocares (Shanghai) Inc. | Chimeric antigen receptor (car) constructs and nk cells expressing car constructs |
| CN112795543B (zh) * | 2021-02-04 | 2022-09-27 | 华中农业大学 | 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用 |
| GB202102049D0 (en) * | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| CN113736810B (zh) * | 2021-09-08 | 2024-05-24 | 苏州因特药物研发有限公司 | 构建体、载体、蛋白、细胞、制备方法、产品及应用 |
| CN114129718B (zh) * | 2021-10-19 | 2024-05-03 | 华东师范大学 | 一种用于体内自组装car-t的纳米递送系统及其制备方法和应用 |
| CN114558126B (zh) * | 2021-11-04 | 2024-11-08 | 苏州大学附属第一医院 | 序贯输注cd19 car-t和bcma car-t细胞在急性白血病患者免疫介导血小板输注无效中的联合应用 |
| US20250332197A1 (en) * | 2022-03-18 | 2025-10-30 | Sunshine Lake Pharma Co., Ltd. | Claudin18.2 humanized antibody and application thereof |
| CA3260584A1 (en) | 2022-07-05 | 2024-01-11 | Neomics Pharmaceuticals Llc | CHIMERIC ANTIGENIC RECEPTOR COMPRISING A BCMA NANOBODY LINKED TO A CHIMERIC INTRACELLULAR SIGNALING DOMAIN |
| WO2024189583A1 (en) * | 2023-03-15 | 2024-09-19 | Kyoto Prefectural Public University Corporation | Peptide expression constructs and uses thereof |
| CN116516007B (zh) * | 2023-04-18 | 2024-01-19 | 华中科技大学同济医学院附属协和医院 | Cd19表达的检测方法 |
| WO2025160432A1 (en) * | 2024-01-26 | 2025-07-31 | Poseida Therapeutics, Inc. | Methods and compositions for enhancing in vivo persistence and potency of cell therapy |
Family Cites Families (164)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6531A (en) | 1849-06-19 | Beed musical instrument | ||
| US7094A (en) | 1850-02-12 | Connecting trucks with car-bodies | ||
| US568A (en) | 1838-01-09 | Sphebometeb for | ||
| US451A (en) | 1837-11-04 | Island | ||
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4965197A (en) | 1987-06-12 | 1990-10-23 | Massachusetts Institute Of Technology | Coryneform expression and secretion system |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| CA2032914A1 (en) | 1989-12-26 | 1991-06-27 | Peter C.K. Lau | Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| WO1993018181A1 (en) | 1992-03-13 | 1993-09-16 | Cornell Research Foundation, Inc. | Synthetic gene sequence for a signal peptide |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6805861B2 (en) | 1996-01-17 | 2004-10-19 | Imperial College Innovations Limited | Immunotherapy using cytotoxic T lymphocytes (CTL) |
| AU4645697A (en) | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aav4 vector and uses thereof |
| EP0930892A1 (en) | 1996-10-16 | 1999-07-28 | The Johns Hopkins University | Cytokine enhanced immunotherapy for brain tumors |
| US6348584B1 (en) | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| EP1021549A2 (en) | 1997-09-19 | 2000-07-26 | Sequitur, Inc. | SENSE mRNA THERAPY |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| KR100316347B1 (ko) | 1998-09-15 | 2002-08-27 | 한미약품(주) | 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법 |
| WO2002005146A2 (en) | 2000-07-10 | 2002-01-17 | Xencor, Inc. | Method for disigning protein libraries with altered immunogenicity |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| DE10057397A1 (de) | 2000-11-18 | 2002-05-23 | Hella Kg Hueck & Co | Vorrichtung zur Ölstandsmessung |
| EP1436316B1 (en) | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
| WO2002092134A1 (en) | 2001-05-14 | 2002-11-21 | Cell Genesys, Inc. | Lentiviral vectors encoding clotting factors for gene therapy |
| ATE291925T1 (de) | 2001-06-05 | 2005-04-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
| ATE527347T1 (de) | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
| CA2462628C (en) | 2001-10-02 | 2019-08-20 | Institut Clayton De La Recherche | Restricted expression lentiviral vectors |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| EP1463805B1 (en) | 2001-12-17 | 2014-10-22 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| GB0202018D0 (en) | 2002-01-29 | 2002-03-13 | Sense Proteomic Ltd | Tag and method |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| GB0217033D0 (en) | 2002-07-23 | 2002-08-28 | Delta Biotechnology Ltd | Gene and polypeptide sequences |
| GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
| ES2348868T3 (es) | 2002-12-13 | 2010-12-16 | Genetix Pharmaceuticals Inc. | Vectores retrovirales terapeuticos para terapia genica. |
| AU2004204942A1 (en) | 2003-01-08 | 2004-07-29 | Xencor, Inc | Novel proteins with altered immunogenicity |
| ATE532793T1 (de) | 2003-07-03 | 2011-11-15 | Avatar Biotechnologies Inc | Verfahren zur herstellung von molekülen mit verminderter immunogenität |
| GB0316089D0 (en) | 2003-07-09 | 2003-08-13 | Xo Bioscience Ltd | Differentiation method |
| JP4733635B2 (ja) * | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| US20070141666A1 (en) | 2003-09-26 | 2007-06-21 | Applied Research Systems Ars Holding N.V. | Leader sequences for use in production of proteins |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2006042333A2 (en) | 2004-10-12 | 2006-04-20 | Xencor, Inc. | Prediction and assessment of immunogenicity |
| DE23193606T1 (de) | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| EP1757703A3 (en) | 2005-08-24 | 2007-12-05 | Medizinische Hochschule Hannover | Self-inactivating retroviral vector |
| JP2007054069A (ja) | 2005-08-24 | 2007-03-08 | Medizinische Hochschule Hannover | 自己不活性化レトロウイルスベクター |
| EP1757702A1 (en) | 2005-08-24 | 2007-02-28 | Medizinische Hochschule Hannover | Self-inactivating gammaretroviral vector |
| US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| US8603457B2 (en) | 2005-12-02 | 2013-12-10 | University Of Rochester | Nonsense suppression and genetic codon alteration by targeted modification |
| US8706219B2 (en) | 2005-12-22 | 2014-04-22 | Board Of Regents, The University Of Texas System | Method and apparatus for monitoring an organ of a patient |
| KR100787393B1 (ko) * | 2006-03-23 | 2007-12-21 | 학교법인 한림대학교 | 세포 도입성 ｆｋ506 결합 단백질의 융합 단백질 |
| DE102006044841A1 (de) | 2006-09-22 | 2008-04-03 | Wacker Chemie Ag | Signalpeptid zur Produktion von rekombinanten Proteinen |
| DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
| US20090181458A1 (en) | 2006-12-04 | 2009-07-16 | Thomas David Reed | Tubulo-vesicular structure localization signals |
| WO2008140615A2 (en) | 2006-12-21 | 2008-11-20 | Novozymes, Inc. | Modified messenger rna stabilizing sequences for expressing genes in bacterial cells |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| EP2132322A4 (en) | 2007-03-02 | 2013-02-20 | Richmond Chemical Corp | METHOD FOR INCREASING YIELD AND IMPROVING PURIFICATION OF PRODUCTS FROM REACTIONS WITH TRANSAMINASE |
| DK2147104T3 (en) | 2007-05-21 | 2015-12-14 | Danisco Us Inc | USING A ASPARAGINPROTEASE- (NSP24) SIGNAL SEQUENCE FOR heterologous protein EXPRESSION |
| EP2173378B1 (en) | 2007-06-27 | 2014-03-19 | Admune Therapeutics LLC | Complexes of il-15 and il-15ralpha and uses thereof |
| US8039214B2 (en) | 2007-06-29 | 2011-10-18 | Cellscript, Inc. | Synthesis of tagged nucleic acids |
| ES2708856T3 (es) | 2007-08-03 | 2019-04-11 | Pasteur Institut | Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales |
| US9809797B2 (en) | 2007-10-03 | 2017-11-07 | National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology | Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression |
| EP2072618A1 (en) | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US8530636B2 (en) | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
| WO2010014922A2 (en) | 2008-08-01 | 2010-02-04 | The Regents Of The University Of Michigan | Protein purification tags and uses thereof |
| WO2010042490A1 (en) | 2008-10-06 | 2010-04-15 | Boston Medical Center Corporation | A single lentiviral vector system for induced pluripotent (ips) stem cells derivation |
| EP2401365B1 (en) | 2009-02-24 | 2016-04-27 | The Scripps Research Institute | Reengineering mrna primary structure for enhanced protein production |
| MX355507B (es) | 2009-03-09 | 2018-04-19 | Bioatla Llc | Proteinas mirac. |
| EP2414524B1 (en) | 2009-04-03 | 2017-08-23 | Centre National De La Recherche Scientifique | Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements |
| US20120164118A1 (en) | 2009-05-04 | 2012-06-28 | Fred Hutchinson Cancer Research Center | Cocal vesiculovirus envelope pseudotyped retroviral vectors |
| AU2010250452B2 (en) | 2009-05-20 | 2014-06-05 | Toray Industries, Inc. | Cell membrane-permeable peptides |
| US8399625B1 (en) | 2009-06-25 | 2013-03-19 | ESBATech, an Alcon Biomedical Research Unit, LLC | Acceptor framework for CDR grafting |
| EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| EA022786B1 (ru) | 2009-07-31 | 2016-03-31 | Этрис Гмбх | Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков |
| KR101410845B1 (ko) | 2009-09-10 | 2014-06-23 | 바이오콘 리미티드 | 새로운 프로리파제-보바인 트립시노겐 융합 단백질 |
| EP2478002B1 (en) | 2009-09-18 | 2015-02-25 | University Of Houston | Small peptide modulators of potassium channel trafficking |
| US20130012687A1 (en) | 2009-09-21 | 2013-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Inducible self-cleaving protease tag and method of purifying recombinant proteins using the same |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| EP2501414B1 (en) | 2009-11-17 | 2018-01-10 | The Trustees Of The University Of Pennsylvania | Smndelta7 degron: novel compositions and methods of use |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| ES2769129T3 (es) | 2009-12-07 | 2020-06-24 | Univ Pennsylvania | Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células |
| WO2011109726A2 (en) | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| WO2011130624A2 (en) | 2010-04-16 | 2011-10-20 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| US9314516B2 (en) | 2010-05-04 | 2016-04-19 | Cassian Yee | Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses |
| GB201008682D0 (en) | 2010-05-25 | 2010-07-07 | Vib Vzw | Epitope tag for affinity based applications |
| JP6251570B2 (ja) | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法 |
| US9512401B2 (en) | 2010-10-01 | 2016-12-06 | Board Of Regents, The University Of Texas System | B and T lymphocyte attenuator marker for use in adoptive T-cell therapy |
| HRP20181315T1 (hr) | 2010-11-22 | 2018-10-19 | Amicus Therapeutics, Inc. | Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012083424A1 (en) | 2010-12-21 | 2012-06-28 | The University Of Western Ontario | Novel amino acid linker sequences for ligand immobilization |
| WO2012092374A2 (en) | 2010-12-31 | 2012-07-05 | Short Jay M | Express humanization of antibodies |
| EP2708561A4 (en) | 2011-03-15 | 2014-09-24 | Univ Yonsei Iacf | BIO-PIN |
| RU2632651C2 (ru) | 2011-05-11 | 2017-10-06 | Чилдрен'С Медикал Сентер Корпорейшн | Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| JP6053688B2 (ja) | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| JP6267644B2 (ja) * | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗ｃｄ２２キメラ抗原受容体 |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| US20140359799A1 (en) | 2011-12-23 | 2014-12-04 | Case Western Reserve University | Targeted gene modification using hybrid recombinant adeno-associated virus |
| WO2013091661A2 (en) | 2011-12-23 | 2013-06-27 | Aarhus Universitet | Proteolytic resistant protein affinity tag |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| MX360368B (es) | 2012-04-27 | 2018-10-29 | Bioatla Llc | Regiones de anticuerpo modificado y sus usos. |
| KR101520534B1 (ko) | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| EP3553089A1 (en) | 2012-05-10 | 2019-10-16 | Bioatla, LLC | Multi-specific monoclonal antibodies |
| WO2013172926A1 (en) * | 2012-05-14 | 2013-11-21 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
| DK3578201T3 (da) | 2012-06-28 | 2023-05-08 | Univ Of Central Florida Research Foundation Incorporated | Fremgangsmåder og sammensætninger til naturlige dræberceller |
| RU2015103816A (ru) | 2012-07-09 | 2016-08-27 | Ф.Хоффманн-Ля Рош Аг | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E |
| GB201212902D0 (en) | 2012-07-20 | 2012-09-05 | Univ Singapore | Combinatoric encoding methods for microarrays |
| EP2899199B1 (en) | 2012-09-19 | 2019-07-03 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053880A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014056813A1 (en) | 2012-10-08 | 2014-04-17 | F. Hoffmann-La Roche Ag | Cell penetrating peptides which bind irf5 |
| US20150359853A1 (en) | 2012-10-24 | 2015-12-17 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| US9444624B2 (en) | 2012-11-02 | 2016-09-13 | Facebook, Inc. | Providing user authentication |
| EP3415525B1 (en) | 2012-12-07 | 2022-01-05 | Phion Therapeutics Limited | An amphipathic peptide |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| WO2014121005A1 (en) | 2013-02-01 | 2014-08-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Retroviral vector packaging cell lines and methods of purifying and producing retroviral particles |
| IL305629A (en) * | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| US9675633B2 (en) * | 2013-03-14 | 2017-06-13 | Board Of Regents, The University Of Texas System | miRNA for treating cancer and for use with adoptive immunotherapies |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| JP6684215B2 (ja) * | 2013-08-28 | 2020-04-22 | ピーシーアイ バイオテック エイエス | 予防接種用化合物および免疫化用化合物、ならびに予防接種方法および免疫化方法 |
| WO2015039100A1 (en) | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
| AU2014337367B2 (en) * | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Peptidic chimeric antigen receptor T cell switches and uses thereof |
| GB201318347D0 (en) | 2013-10-16 | 2013-11-27 | Ucl Business Plc | Retroviral vectors |
| ES2913205T3 (es) | 2014-05-13 | 2022-06-01 | Bioatla Inc | Proteínas biológicas activas condicionalmente |
| PT3149025T (pt) | 2014-05-21 | 2019-08-01 | Entrada Therapeutics Inc | Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos |
| BR112016027773B1 (pt) | 2014-05-29 | 2023-12-26 | Procell Therapeutics Inc. | Proteína recombinante célula-penetrante de toxina botulínica,composição farmacêutica, composição para um agente dérmico externo e composição cosmética |
| US20160060313A1 (en) | 2014-08-27 | 2016-03-03 | Daewoong Jo | Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Angiogenic Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Angiogenic Compositions Comprising the Same |
| US10513699B2 (en) | 2014-09-03 | 2019-12-24 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
| US20170239294A1 (en) | 2014-10-15 | 2017-08-24 | Novartis Ag | Compositions and methods for treating b-lymphoid malignancies |
| WO2016113203A1 (en) * | 2015-01-12 | 2016-07-21 | Pieris Ag | Engineered t cells and uses therefor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| US11248058B2 (en) * | 2015-02-19 | 2022-02-15 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| CA3149413C (en) | 2015-04-10 | 2025-07-08 | Feldan Bio Inc. | Polypeptide-based carrier agents to improve the transduction efficiency of polypeptide cargo to cytosol in target eukaryotic cells and their uses, methods, and related kits |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| WO2016210350A1 (en) | 2015-06-25 | 2016-12-29 | Amyris, Inc. | Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds |
| US10550379B2 (en) | 2015-06-29 | 2020-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Degron fusion constructs and methods for controlling protein production |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| EP3347375B1 (en) | 2015-09-10 | 2020-12-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-cd276 chimeric antigen receptors |
| WO2017175072A1 (en) | 2016-04-08 | 2017-10-12 | Feldan Bio Inc. | Peptide shuttle based gene disruption |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| KR20230100748A (ko) * | 2016-07-28 | 2023-07-05 | 노파르티스 아게 | 키메라 항원 수용체 및 pd-1 억제제의 조합 요법 |
| US11241485B2 (en) | 2017-06-12 | 2022-02-08 | Obsidian Therapeutics, Inc. | PDE5 compositions and methods for immunotherapy |
-
2018
- 2018-03-02 AU AU2018227583A patent/AU2018227583B2/en active Active
- 2018-03-02 KR KR1020197029002A patent/KR102746901B1/ko active Active
- 2018-03-02 CN CN201880025103.XA patent/CN110831961B/zh active Active
- 2018-03-02 SG SG10202001869VA patent/SG10202001869VA/en unknown
- 2018-03-02 WO PCT/US2018/020741 patent/WO2018161017A1/en not_active Ceased
- 2018-03-02 JP JP2019568594A patent/JP7341900B2/ja active Active
- 2018-03-02 SG SG11201907922PA patent/SG11201907922PA/en unknown
- 2018-03-02 EP EP18760420.2A patent/EP3589646A4/en active Pending
-
2023
- 2023-08-11 AU AU2023214349A patent/AU2023214349C1/en active Active
- 2023-08-30 JP JP2023139792A patent/JP2023164900A/ja active Pending
-
2025
- 2025-10-01 JP JP2025165390A patent/JP2025185029A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| JP2022130485A (ja) | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント | |
| US11999773B2 (en) | Anti-BCMA chimeric antigen receptors | |
| JP2020525536A5 (enExample) | ||
| US20220025001A1 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
| US20200399393A1 (en) | Dimeric Antigen Receptors | |
| KR20230129983A (ko) | 조작된 세포 요법을 위한 표적화된 사이토카인 구축물 | |
| TW202023580A (zh) | 使用靶特異性融合蛋白進行ｔｃｒ再程式化之組合物及方法 | |
| CN114391021B (zh) | TGF-β受体和使用方法 | |
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| CA3177394A1 (en) | Method and compositions for cellular immunotherapy | |
| JP2025511872A (ja) | 多部位受容体及びシグナル伝達複合体 | |
| US20220133792A1 (en) | Signaling platforms for chimeric antigen receptor t cells | |
| US20220251168A1 (en) | Dimeric Antigen Receptors (DAR) that Bind BCMA | |
| US20200347148A1 (en) | Methods for enhancing and maintaining car-t cell efficacy | |
| US20240131068A1 (en) | Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same | |
| CN114828862A (zh) | 使用融合蛋白进行tcr重编程的组合物和方法 | |
| WO2022036224A1 (en) | Chimeric antigen receptor t cells for treating autoimmunity | |
| US20250121007A1 (en) | Compositions for the treatment of cancer | |
| WO2026015853A1 (en) | Enhancing activity and persistence of car-nk cells for the treatment of cancer and autoimmune diseases | |
| WO2026042055A1 (en) | Dual targeting cancer cell therapy for cd19 and cd20 | |
| CN121532497A (zh) | Cldn18.2和gucy2c靶向拮抗剂组合疗法 |